SCHEMBL2548914

SCHEMBL2548914

COCCn1c(-c2c[nH]c(-c3ccc4scnc4c3)n2)nc2cccnc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ GLA P06280 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ MAP3K11 Q16584 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ CASR P41180 1/20 0.33
▸ SYK P43405 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14575953 0.89 NPC1 (0.35) KDM4EGLAGAARECQLHSD17B10
SCHEMBL14575762 0.89 ALOX15 (0.36) KDM4EGLAGAARECQLHSD17B10
SCHEMBL14576676 0.88 KDM4E (0.37) KDM4EGLAGAARECQLHSD17B10
SCHEMBL2555588 0.88 HPGD (0.49) TP53NPSR1KDM4EGAARECQL
SCHEMBL2552224 0.84 CASR (0.41) KDM4ERECQLHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL14575714 0.84 NPC1 (0.36) KDM4EGLAGAARECQLHSD17B10
SCHEMBL14616791 0.84 RIPK2 (0.43) TP53MAPTNPSR1KDM4EGLA
SCHEMBL2554816 0.83 KDM4E (0.37) TP53KDM4ERECQLHSD17B10ALDH1A1
SCHEMBL14576187 0.83 MAP3K11 (0.34) NPC1POLBALOX15MAPK1RAB9A
SCHEMBL14576307 0.83 RIPK2 (0.36) NPC1POLBALOX15MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 TP53 670/4885MAPT 2704/4885NPSR1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback